EN
中
凌科专注于
「癌症」与「自身免疫疾病」的
创新药物研发
Lynk is dedicated to
developing innovative drugs
for cancer and autoimmune diseases
研发领域
R & D
产品管线
PIPELINE
注：LNK01001的类风湿性关节炎和强直性脊椎炎在大中华地区的商业化权益于2022年授予先声药业。
Note: China marketing rights of rheumatoid arthritis and ankylosing spondylitis of LNK01001 were granted to Simcere Pharmaceutical in 2022.
